Another pathway, TGF-β1-mediated SMAD pathway inhibition, can result in the attenuation of cardiac impairment following myocardial infarction (MI), and this can be achieved by Apigenin, which exhibits cytostatic and cytoprotective activity [32,33]. This evidence concerns the gene TGFB1 and myocardial infarction.